Literature DB >> 21892620

The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis.

Angèle Nalbandian1, Sandra Donkervoort, Eric Dec, Mallikarjun Badadani, Veeral Katheria, Prachi Rana, Christopher Nguyen, Jogeshwar Mukherjee, Vincent Caiozzo, Barbara Martin, Giles D Watts, Jouni Vesa, Charles Smith, Virginia E Kimonis.   

Abstract

Inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD) is a progressive, fatal genetic disorder with variable penetrance, predominantly affecting three main tissue types: muscle (IBM), bone (PDB), and brain (FTD). IBMPFD is caused by mutations in the ubiquitously expressed valosin-containing protein (VCP) gene, a member of the AAA-ATPase superfamily. The majority of individuals who develop IBM have progressive proximal muscle weakness. Muscle biopsies reveal rimmed vacuoles and inclusions that are ubiquitin- and TAR DNA binding protein-43 (TDP-43)-positive using immunohistochemistry. PDB, seen in half the individuals, is caused by overactive osteoclasts and is associated clinically with pain, elevated serum alkaline phosphatase, and X-ray findings of coarse trabeculation and sclerotic lesions. FTD diagnosed at a mean age of 55 years in a third of individuals is characterized clinically by comprehension deficits, dysnomia, dyscalculia, and social unawareness. Ubiquitin- and TDP-43-positive neuronal inclusions are also found in the brain. Genotype-phenotype correlations are difficult with marked intra-familial and inter-familial variations being seen. Varied phenotypes within families include frontotemporal dementia, amyotrophic lateral sclerosis, Parkinsonism, myotonia, cataracts, and anal incompetence, among others. Cellular and animal models indicate pathogenetic disturbances in IBMPFD tissues including altered protein degradation, autophagy pathway alterations, apoptosis, and mitochondrial dysfunction. Currently, mouse and drosophila models carrying VCP mutations provide insights into the human IBMPFD pathology and are useful as tools for preclinical studies and testing of therapeutic strategies. In this review, we will explore the pathogenesis and clinical phenotype of IBMPFD caused by VCP mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892620     DOI: 10.1007/s12031-011-9627-y

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  88 in total

Review 1.  Autophagy gone awry in neurodegenerative diseases.

Authors:  Esther Wong; Ana Maria Cuervo
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

Review 2.  Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia.

Authors:  R S Turner; L C Kenyon; J Q Trojanowski; N Gonatas; M Grossman
Journal:  Ann Neurol       Date:  1996-02       Impact factor: 10.422

3.  Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia.

Authors:  M J Kovach; B Waggoner; S M Leal; D Gelber; R Khardori; M A Levenstien; C A Shanks; G Gregg; M T Al-Lozi; T Miller; W Rakowicz; G Lopate; J Florence; G Glosser; Z Simmons; J C Morris; M P Whyte; A Pestronk; V E Kimonis
Journal:  Mol Genet Metab       Date:  2001-12       Impact factor: 4.797

4.  Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone.

Authors:  Sara K Custer; Manuela Neumann; Hongbo Lu; Alexander C Wright; J Paul Taylor
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

Review 5.  Contemporary approaches to Alzheimer's disease and frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Methods Mol Biol       Date:  2011

Review 6.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

7.  Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family.

Authors:  Eun-Joo Kim; Young-Eun Park; Dae-Seong Kim; Bo-Young Ahn; Hyang-Sook Kim; Young Hee Chang; Seong-Jang Kim; Hak-Jin Kim; Ho-Won Lee; William W Seeley; SangYun Kim
Journal:  Arch Neurol       Date:  2011-02-14

8.  TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97.

Authors:  Gillian P Ritson; Sara K Custer; Brian D Freibaum; Jake B Guinto; Dyanna Geffel; Jennifer Moore; Waixing Tang; Matthew J Winton; Manuela Neumann; John Q Trojanowski; Virginia M-Y Lee; Mark S Forman; J Paul Taylor
Journal:  J Neurosci       Date:  2010-06-02       Impact factor: 6.167

Review 9.  Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia.

Authors:  Conrad C Weihl; Alan Pestronk; Virginia E Kimonis
Journal:  Neuromuscul Disord       Date:  2009-04-19       Impact factor: 4.296

10.  VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease.

Authors:  Mallikarjun Badadani; Angèle Nalbandian; Giles D Watts; Jouni Vesa; Masashi Kitazawa; Hailing Su; Jasmin Tanaja; Eric Dec; Douglas C Wallace; Jogeshwar Mukherjee; Vincent Caiozzo; Matthew Warman; Virginia E Kimonis
Journal:  PLoS One       Date:  2010-10-05       Impact factor: 3.240

View more
  66 in total

1.  Global gene profiling of VCP-associated inclusion body myopathy.

Authors:  Angèle Nalbandian; Svetlana Ghimbovschi; Shlomit Radom-Aizik; Eric Dec; Jouni Vesa; Barbara Martin; Susan Knoblach; Charles Smith; Eric Hoffman; Virginia E Kimonis
Journal:  Clin Transl Sci       Date:  2012-04-04       Impact factor: 4.689

2.  In vitro studies in VCP-associated multisystem proteinopathy suggest altered mitochondrial bioenergetics.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Arianna Gomez; Naomi Walker; Hailing Su; Andrew Dunnigan; Marilyn Chwa; Jouni Vesa; M C Kenney; Virginia E Kimonis
Journal:  Mitochondrion       Date:  2015-02-25       Impact factor: 4.160

3.  Altered intersubunit communication is the molecular basis for functional defects of pathogenic p97 mutants.

Authors:  Wai Kwan Tang; Di Xia
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

4.  The Myoblast C2C12 Transfected with Mutant Valosin-Containing Protein Exhibits Delayed Stress Granule Resolution on Oxidative Stress.

Authors:  Carlos J Rodriguez-Ortiz; Julio C Flores; Joanna A Valenzuela; Gema J Rodriguez; Joannee Zumkehr; Diana N Tran; Virginia E Kimonis; Masashi Kitazawa
Journal:  Am J Pathol       Date:  2016-04-20       Impact factor: 4.307

5.  The requirement for Cdc48/p97 in nuclear protein quality control degradation depends on the substrate and correlates with substrate insolubility.

Authors:  Pamela S Gallagher; Sarah V Clowes Candadai; Richard G Gardner
Journal:  J Cell Sci       Date:  2014-02-25       Impact factor: 5.285

6.  A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Mallikarjun Badadani; Hong Z Yin; Christopher Nguyen; Veeral Katheria; Giles Watts; Jogeshwar Mukherjee; Jouni Vesa; Vincent Caiozzo; Tahseen Mozaffar; John H Weiss; Virginia E Kimonis
Journal:  Muscle Nerve       Date:  2012-11-21       Impact factor: 3.217

7.  A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene.

Authors:  Jake Plewa; Abhilasha Surampalli; Marie Wencel; Merit Milad; Sandra Donkervoort; Vincent J Caiozzo; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Neuromuscul Disord       Date:  2018-06-27       Impact factor: 4.296

8.  Phenotypic variability in three families with valosin-containing protein mutation.

Authors:  S Spina; A D Van Laar; J R Murrell; R L Hamilton; J K Kofler; F Epperson; M R Farlow; O L Lopez; J Quinlan; S T DeKosky; B Ghetti
Journal:  Eur J Neurol       Date:  2012-08-20       Impact factor: 6.089

9.  Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia.

Authors:  S G Mehta; M Khare; R Ramani; G D J Watts; M Simon; K E Osann; S Donkervoort; E Dec; A Nalbandian; J Platt; M Pasquali; A Wang; T Mozaffar; C D Smith; V E Kimonis
Journal:  Clin Genet       Date:  2012-10-04       Impact factor: 4.438

10.  Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis.

Authors:  Paloma González-Pérez; Elizabeth T Cirulli; Vivian E Drory; Ron Dabby; Puiu Nisipeanu; Ralph L Carasso; Menachem Sadeh; Andrew Fox; Barry W Festoff; Peter C Sapp; Diane McKenna-Yasek; David B Goldstein; Robert H Brown; Sergiu C Blumen
Journal:  Neurology       Date:  2012-11-14       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.